GFM
OBIO icon

GF Fund Management’s Orchestra BioMed OBIO Stock Holding History

GF Fund Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.36K Buy
1,260
+151
+14% +$643 ﹤0.01% 604
2025
Q4 		$4.6K Buy
+1,109
New +$4.47K ﹤0.01% 625

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

GF Fund Management's OBIO Position: Q1 2026 in Review

GF Fund Management increased its Orchestra BioMed (OBIO) stake by 14% in Q1 2026, buying an estimated $643 and bringing the position to 1,260 shares worth $5.36K. The position accounts for ﹤0.01% of the portfolio, ranked #604.

GF Fund Management first reported a position in OBIO in Q4 2025 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • GF Fund Management held 1,260 shares of Orchestra BioMed worth $5.36K as of Q1 2026.
  • GF Fund Management bought 151 Orchestra BioMed shares in Q1 2026, an estimated $643.
  • Orchestra BioMed made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #604 holding.
  • GF Fund Management first reported a position in Orchestra BioMed in Q4 2025 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.